<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01493284</url>
  </required_header>
  <id_info>
    <org_study_id>1105</org_study_id>
    <nct_id>NCT01493284</nct_id>
  </id_info>
  <brief_title>Portico TAVI Implant With Transfemoral Delivery System</brief_title>
  <official_title>Assessment Of The St. Jude Medical Portico™ Transcatheter Aortic Valve Implant (TAVI) And The SJM TAVI Transfemoral Delivery System (Portico TF EU)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Jude Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Jude Medical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and effectiveness of the SJM Portico
      Transcatheter Heart Valve and the SJM TAVI Transfemoral Transcatheter delivery system in
      subjects with severe symptomatic aortic stenosis (AS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Data will be collected at baseline, procedure, discharge, 30 days post implant, 3 months post
      implant, 6 months post implant, and 12 months post implant.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All Cause Mortality</measure>
    <time_frame>30 days</time_frame>
    <description>Number of participants that reported all cause mortality</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Select Cardiovascular Adverse Events</measure>
    <time_frame>30 days</time_frame>
    <description>Number of participants with select cardiovascular adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant NYHA Classification at Day 30</measure>
    <time_frame>day 30</time_frame>
    <description>The New York Heart Association (NYHA) functional classification system relates symptoms to everyday activities and the patient's quality of life.
Class I. Patients with cardiac disease but without resulting limitation of physical activity.
Class II. Patients with cardiac disease resulting in slight limitation of physical activity. They are comfortable at rest.
Class III. Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest.
Class IV. Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of heart failure or the anginal syndrome may be present even at rest.
The Criteria Committee of the New York Heart Association. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels. 9th ed. Boston, Mass: Little, Brown &amp; Co; 1994:253-256.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Acute Device Success</measure>
    <time_frame>7 days</time_frame>
    <description>Successful vascular access, delivery and deployment of the device and successful retrieval of the delivery system
Correct position of the device in the proper anatomical location
Intended performance of the prosthetic heart valve (Aortic Valve Area &gt;1.2 cm2 and mean aortic valve gradient &lt;20 mmHg or peak velocity &lt;3 m/s, without moderate or severe prosthetic valve AR)
Only one valve implanted in the proper anatomical location</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">222</enrollment>
  <condition>Symptomatic Aortic Stenosis</condition>
  <arm_group>
    <arm_group_label>Transfemoral Access</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transfemoral Access for transcatheter aortic valve implant</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcatheter Aortic Valve Implantation</intervention_name>
    <description>Placement of the SJM Portico aortic valve with a transfemoral delivery system</description>
    <arm_group_label>Transfemoral Access</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject has given written study Informed Consent for participation prior to procedure.

          2. Subject is ≥ 18 years of age or legal age in host country.

          3. Subject's aortic annulus diameter meets the range indicated in the Instructions for
             use as measured by echocardiogram (echo) or CT conducted within the past 90 days.

          4. Subject has senile degenerative aortic stenosis with echocardiography (echo) derived
             mean gradient &gt;40mmHg or jet velocity greater than 4.0 m/s or an initial valve area of
             &lt;1.0 cm2 (or aortic valve area index ≤ 0.6 cm2/m2). (Baseline measurement taken by
             echo within 30 days of procedure).

          5. Subject has symptomatic aortic stenosis as demonstrated by NYHA Functional
             Classification of II or greater.

          6. Subject is deemed high operable risk and suitable for TAVI per the medical opinion of
             the Subject Selection Committee (See Section 3.1 for the definition of the Subject
             Selection Committee)

          7. Subject's predicted operative mortality or serious, irreversible morbidity risk is
             &lt;50% at 30 days.

          8. In the opinion of the Subject Selection Committee and based upon angiographic
             measurements, the subject has suitable peripheral vessels and aorta to allow for
             access of the 18 French delivery system.

          9. Subject has structurally normal cardiac anatomy.

         10. Subject is willing and able to comply with all required follow-up evaluations.

        Exclusion Criteria:

          1. Subject has a history of a cerebral vascular accident (CVA) or transient ischemic
             attack (TIA) within the past 6 months (≤180 days) of the index procedure.

          2. Subject has carotid artery disease requiring intervention.

          3. Subject has evidence of a myocardial infarction (MI) within the past 6 months (≤180
             days) of the index procedure.

          4. Subject has hypertrophic cardiomyopathy.

          5. Subject has a native aortic valve that is congenitally unicuspid, bicuspid,
             quadricuspid or non-calcified as seen by echocardiography.

          6. Subject has mitral or tricuspid valvular regurgitation (&gt;grade III) or moderate to
             severe mitral stenosis.

          7. Subject has aortic root angulation &gt;70 degrees (horizontal aorta).

          8. Subject has a pre-existing prosthetic valve or prosthetic ring in any position.

          9. Subject refuses blood transfusion or surgical valve replacement.

         10. Subject has left ventricular ejection fraction (LVEF) &lt; 20%.

         11. The subject has documented, untreated coronary artery disease (CAD) requiring
             revascularization.

         12. Subject has severe basal septal hypertrophy.

         13. Subject has had a percutaneous interventional or other invasive cardiac or peripheral
             procedure ≤ 14 days of the index procedure.

         14. Subject has a history of or has active endocarditis.

         15. Subject has echocardiographic evidence of intracardiac mass, thrombus, or vegetation.

         16. Subject has hemodynamic instability (requiring inotropic support or mechanical heart
             assistance).

         17. Subject is in acute pulmonary edema or requiring intravenous diuretic therapy to
             stabilize heart failure.

         18. Subject with significant pulmonary disease.

         19. Subject has significant chronic steroid use.

         20. Subject has a known hypersensitivity or contraindication to anticoagulant or
             antiplatelet medication.

         21. Subject has renal insufficiency as evidenced by a serum creatinine &gt; 3.0 mg/dL
             (265µmol/L) or end-stage renal disease requiring chronic dialysis.

         22. Subject has morbid obesity defined as BMI ≥ 40.

         23. Subject's iliac arteries have severe calcification, tortuosity (&gt;two 90 degree bends),
             diameter &lt;6mm, or subject has had an aorto-femoral bypass.

         24. Subject has ongoing infection or sepsis.

         25. Subject has blood dyscrasias (leukopenia, acute anemia, thrombocytopenia, history of
             bleeding diathesis, or coagulopathy).

         26. Subject has a current autoimmune disease that, in the opinion of the Principal
             Investigator precludes the subject from study participation.

         27. Subject has significant aortic disease, including:

               -  aortic abdominal aneurysm (AAA) ≥ 4cm

               -  thoracic aneurysm (defined as a maximal luminal diameter of 5 cm or greater)

               -  marked tortuosity

               -  significant aortic arch atheroma or narrowing of the abdominal or thoracic aorta

               -  severe tortuosity of the thoracic aorta.

         28. Subject has a pre-existing endovascular stent graft in the supra- or infrarenal aorta
             or pre-existing stent grafts in the ileo-femoral arteries.

         29. Subject has an active peptic ulcer or has had gastrointestinal (GI) bleeding within
             the past 90 days prior to the index procedure.

         30. Subject is currently participating in another investigational drug or device study.

         31. Subject requires emergency surgery for any reason.

         32. Subject has a life expectancy &lt; 12 months.

         33. Subject has other medical, social or psychological conditions that, in the opinion of
             the Subject Selection Committee, preclude the subject from study participation.

         34. Subject is suffering from dementia or admitted to a chronic care facility which would
             fundamentally complicate rehabilitation from the procedure or compliance with
             follow-up visits.

         35. Subject has a known allergy to contrast media, nitinol alloys, porcine tissue, or
             bovine tissue.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ganesh Manoharan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Victoria Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Adelaide Royal Hospital</name>
      <address>
        <city>Adelaide</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet Copenhagen</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kerckhoff Klinik</name>
      <address>
        <city>Bad Nauheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heart Center Bernau</name>
      <address>
        <city>Bernau</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik-St. Georg</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität Jena</name>
      <address>
        <city>Jena</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik fur Herzhirurgie Karlruhe GmbH</name>
      <address>
        <city>Karlsruhe</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center Leeuwarden</name>
      <address>
        <city>Leeuwarden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Hospital</name>
      <address>
        <city>Belfast</city>
        <state>Northern Ireland</state>
        <zip>BT12 6BA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glenfield Hospital</name>
      <address>
        <city>Leicester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kings College</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Thomas' Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Derriford Hospital, Plymouth</name>
      <address>
        <city>Plymouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2011</study_first_submitted>
  <study_first_submitted_qc>December 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2011</study_first_posted>
  <results_first_submitted>March 15, 2017</results_first_submitted>
  <results_first_submitted_qc>April 18, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">April 23, 2018</results_first_posted>
  <last_update_submitted>April 18, 2018</last_update_submitted>
  <last_update_submitted_qc>April 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>aortic stenosis</keyword>
  <keyword>aortic valve stenosis</keyword>
  <keyword>valvular heart disease</keyword>
  <keyword>aortic valve replacement</keyword>
  <keyword>transcatheter aortic valve implantation</keyword>
  <keyword>TAVI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constriction, Pathologic</mesh_term>
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Transfemoral</title>
          <description>Transfemoral access</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="222"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="161"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Transfemoral</title>
          <description>Transfemoral access</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="222"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83.0" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="165"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Denmark</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>STS risk score of mortality</title>
          <description>The Society of Thoracic Surgeons (STS) score measures patient risk of operative mortality and morbidity after adult cardiac surgery on a scale that ranges from 0% to 100%, with higher numbers indicating greater risk.</description>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.8" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>NYHA class III/IV</title>
          <description>NYHA Class I: Subjects with cardiac disease but without resulting limitations of physical activity.
NYHA Class II: Subjects with cardiac disease resulting in slight limitation of physical activity.
NYHA Class III: Subjects with cardiac disease resulting in marked limitation of physical activity.
NYHA Class IV: Subjects with cardiac disease resulting in inability to carry on any physical activity without discomfort.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of pulmonary hypertension</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Porcelain aorta</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of atrial fibrillation</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Renal failure/insufficiency</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>All Cause Mortality</title>
        <description>Number of participants that reported all cause mortality</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Transfemoral</title>
            <description>Transfemoral access</description>
          </group>
        </group_list>
        <measure>
          <title>All Cause Mortality</title>
          <description>Number of participants that reported all cause mortality</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="222"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Select Cardiovascular Adverse Events</title>
        <description>Number of participants with select cardiovascular adverse events</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Transfemoral</title>
            <description>Transfemoral access</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Select Cardiovascular Adverse Events</title>
          <description>Number of participants with select cardiovascular adverse events</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="222"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cardiovascular death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myocardial Infarction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stage 3 Acute kidney injury</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disabling (major) stroke</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-disabling (minor) stroke</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Life threatening or disabling bleeding</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participant NYHA Classification at Day 30</title>
        <description>The New York Heart Association (NYHA) functional classification system relates symptoms to everyday activities and the patient's quality of life.
Class I. Patients with cardiac disease but without resulting limitation of physical activity.
Class II. Patients with cardiac disease resulting in slight limitation of physical activity. They are comfortable at rest.
Class III. Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest.
Class IV. Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of heart failure or the anginal syndrome may be present even at rest.
The Criteria Committee of the New York Heart Association. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels. 9th ed. Boston, Mass: Little, Brown &amp; Co; 1994:253-256.</description>
        <time_frame>day 30</time_frame>
        <population>Analysis for participants that completed visit and assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Transfemoral</title>
            <description>Transfemoral access</description>
          </group>
        </group_list>
        <measure>
          <title>Participant NYHA Classification at Day 30</title>
          <description>The New York Heart Association (NYHA) functional classification system relates symptoms to everyday activities and the patient's quality of life.
Class I. Patients with cardiac disease but without resulting limitation of physical activity.
Class II. Patients with cardiac disease resulting in slight limitation of physical activity. They are comfortable at rest.
Class III. Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest.
Class IV. Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of heart failure or the anginal syndrome may be present even at rest.
The Criteria Committee of the New York Heart Association. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels. 9th ed. Boston, Mass: Little, Brown &amp; Co; 1994:253-256.</description>
          <population>Analysis for participants that completed visit and assessment</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>NYHA 1</title>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                  </measurement_list>
                </category>
                <category>
                  <title>NYHA II</title>
                  <measurement_list>
                    <measurement group_id="O1" value="105"/>
                  </measurement_list>
                </category>
                <category>
                  <title>NYHA III</title>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>NYHA IV</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Acute Device Success</title>
        <description>Successful vascular access, delivery and deployment of the device and successful retrieval of the delivery system
Correct position of the device in the proper anatomical location
Intended performance of the prosthetic heart valve (Aortic Valve Area &gt;1.2 cm2 and mean aortic valve gradient &lt;20 mmHg or peak velocity &lt;3 m/s, without moderate or severe prosthetic valve AR)
Only one valve implanted in the proper anatomical location</description>
        <time_frame>7 days</time_frame>
        <population>Successful vascular access, delivery and deployment of the device</population>
        <group_list>
          <group group_id="O1">
            <title>Transfemoral</title>
            <description>Transfemoral access</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Acute Device Success</title>
          <description>Successful vascular access, delivery and deployment of the device and successful retrieval of the delivery system
Correct position of the device in the proper anatomical location
Intended performance of the prosthetic heart valve (Aortic Valve Area &gt;1.2 cm2 and mean aortic valve gradient &lt;20 mmHg or peak velocity &lt;3 m/s, without moderate or severe prosthetic valve AR)
Only one valve implanted in the proper anatomical location</description>
          <population>Successful vascular access, delivery and deployment of the device</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="222"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="216"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1-year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Transfemoral</title>
          <description>Transfemoral access</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="222"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="102" subjects_at_risk="222"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiovascular Death</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="222"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="222"/>
              </event>
              <event>
                <sub_title>Pacemaker implantation</sub_title>
                <counts group_id="E1" events="33" subjects_affected="33" subjects_at_risk="222"/>
              </event>
              <event>
                <sub_title>Heart failure</sub_title>
                <counts group_id="E1" events="47" subjects_affected="37" subjects_at_risk="222"/>
              </event>
              <event>
                <sub_title>Coronary obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="222"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>All-cause death</sub_title>
                <counts group_id="E1" events="29" subjects_affected="29" subjects_at_risk="222"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Stage 3 acute kidney injury</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="222"/>
              </event>
              <event>
                <sub_title>Disabling stroke</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="222"/>
              </event>
              <event>
                <sub_title>Stage 1 acute kidney injury</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="222"/>
              </event>
              <event>
                <sub_title>Stage 2 acute kidney injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="222"/>
              </event>
              <event>
                <sub_title>Non-disabling stroke</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="222"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Life-threatening or disabling bleeding</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="222"/>
              </event>
              <event>
                <sub_title>Major vascular complications</sub_title>
                <counts group_id="E1" events="23" subjects_affected="19" subjects_at_risk="222"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2.2</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="222"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="222"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="222"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="222"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sr Clinical Scientist</name_or_title>
      <organization>St Jude Medical</organization>
      <phone>4159179696</phone>
      <email>alicia.kimber@abbott.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

